NCT02329405

The Effects of PXR Activation on Hepatic Fat Content

PXR-aktivaation Vaikutus Maksan Rasvoittumiseen

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: University of Oulu · Academic / Other
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

This study investigates the effects of pregnane X receptor (PXR) activation on hepatic fat content in healthy volunteers. Rifampicin (an antibiotic and also an efficient PXR activator) and placebo will be given for a week to volunteers. Hepatic fat content is measured with magnetic resonance imaging and blood samples are collected at the end of each study arm. The investigators' hypothesis is that rifampicin causes accumulation of fat to the liver.

Conditions

• Non-alcoholic Fatty Liver Disease

Interventions

Type	Name	Description
DRUG	Rifampicin
DRUG	Placebo

Timeline

• Start date: 2014-12-01
• Primary completion: 2017-01-01
• Completion: 2017-01-01
• First posted: 2014-12-31
• Last updated: 2017-11-01

Locations

1 site across 1 country: Finland